SCHEMBL15712947

SCHEMBL15712947

CC(=O)OCC1CCC(C(C)(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPA P38571 1/20 0.46
ALDH1A1 P00352 4/20 0.38
MAPT P10636 2/20 0.38
EPHX1 P07099 1/20 0.37
APOBEC3A P31941 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
EPHX2 P34913 1/20 0.36
HSD11B1 P28845 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP19A1 P11511 1/20 0.35
RECQL P46063 1/20 0.35
ATM Q13315 1/20 0.35
CDC25B P30305 1/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
JAK3 P52333 1/20 0.34
LMNA P02545 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10861392 0.87 LIPA (0.34) LIPAALDH1A1JAK2JAK1TYK2
SCHEMBL17029138 0.85 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2JAK2JAK1TYK2
SCHEMBL6256094 0.85
SCHEMBL5696892 0.85 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2JAK2JAK1TYK2
Hydrochloric Acid SCHEMBL28064641 0.83
SCHEMBL15706267 0.83 LIPA (0.45) LIPAALDH1A1MAPTEPHX1APOBEC3A
SCHEMBL465420 0.82 ALDH1A1 (0.49) LIPAALDH1A1MAPTEPHX1APOBEC3A
SCHEMBL465394 0.79 LIPA (0.41) LIPAALDH1A1MAPTEPHX1APOBEC3A
SCHEMBL21243330 0.79 TP53 (0.49) LIPAALDH1A1MAPTEPHX1APOBEC3A
SCHEMBL5680245 0.78 ALDH1A1 (0.34) ALDH1A1JAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140134262-A1 METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2014-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140134262-A1 METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS CETP, MTTP, APOB LIPA 8/4885ALDH1A1 2127/4885MAPT 4330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.